Discovering biomarkers for antidepressant response:protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Lam, Raymond W., Milev, Roumen, Rotzinger, Susan, Andreazza, Ana C., Blier, Pierre, Brenner, Colleen, Daskalakis, Zafiris J., Dharsee, Moyez, Downar, Jonathan, Evans, Kenneth R., Farzan, Faranak, Foster, Jane A., Frey, Benicio N., Geraci, Joseph, Giacobbe, Peter, Feilotter, Harriet E., Hall, Geoffrey B., Harkness, Kate L., Hassel, Stefanie, Ismail, Zahinoor, Leri, Francesco, Liotti, Mario, MacQueen, Glenda M., McAndrews, Mary Pat, Minuzzi, Luciano, Müller, Daniel J., Parikh, Sagar V., Placenza, Franca M., Quilty, Lena C., Ravindran, Arun V., Salomons, Tim V., Soares, Claudio N., Strother, Stephen C., Turecki, Gustavo, Vaccarino, Anthony L., Vila-Rodriguez, Fidel, Kennedy, Sidney H. and CAN-BIND Investigator Team (2016). Discovering biomarkers for antidepressant response:protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 16 ,

Abstract

Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. Trial registration: ClinicalTrials.gov identifier NCT01655706. Registered July 27, 2012.

Publication DOI: https://doi.org/10.1186/s12888-016-0785-x
Divisions: Life & Health Sciences > Psychology
Life & Health Sciences
Additional Information: © 2016 Lam et al. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Uncontrolled Keywords: Psychiatry and Mental health
Full Text Link: http://bmcpsych ... 2888-016-0785-x
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Date: 2016-04-16
Authors: Lam, Raymond W.
Milev, Roumen
Rotzinger, Susan
Andreazza, Ana C.
Blier, Pierre
Brenner, Colleen
Daskalakis, Zafiris J.
Dharsee, Moyez
Downar, Jonathan
Evans, Kenneth R.
Farzan, Faranak
Foster, Jane A.
Frey, Benicio N.
Geraci, Joseph
Giacobbe, Peter
Feilotter, Harriet E.
Hall, Geoffrey B.
Harkness, Kate L.
Hassel, Stefanie ( 0000-0001-7240-1581)
Ismail, Zahinoor
Leri, Francesco
Liotti, Mario
MacQueen, Glenda M.
McAndrews, Mary Pat
Minuzzi, Luciano
Müller, Daniel J.
Parikh, Sagar V.
Placenza, Franca M.
Quilty, Lena C.
Ravindran, Arun V.
Salomons, Tim V.
Soares, Claudio N.
Strother, Stephen C.
Turecki, Gustavo
Vaccarino, Anthony L.
Vila-Rodriguez, Fidel
Kennedy, Sidney H.
, CAN-BIND Investigator Team

Download

[img]

Version: Published Version

License: Creative Commons Attribution


Export / Share Citation


Statistics

Additional statistics for this record